An in vivo platform for tumor biomarker assessment

PLoS One. 2011;6(10):e26722. doi: 10.1371/journal.pone.0026722. Epub 2011 Oct 26.

Abstract

Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor heterogeneity. In addition, assessment of biomarkers as indicators of therapy response is confounded by the concomitant use of multiple therapeutic interventions. Herein we report our use of a clinically relevant orthotopic animal model of malignant pleural mesothelioma for investigating tumor biomarkers. Utilizing multi-modality imaging with correlative histopathology, we demonstrate the utility and accuracy of the mouse model in investigating tumor biomarkers--serum soluble mesothelin-related peptide (SMRP) and osteopontin (OPN). This model revealed percentage change in SMRP level to be an accurate biomarker of tumor progression and therapeutic response--a finding consistent with recent clinical studies. This in vivo platform demonstrates the advantages of a validated mouse model for the timely and cost-effective acceleration of human biomarker translational research.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Validation Study

MeSH terms

  • Animals
  • Biomarkers, Tumor / standards*
  • Diagnostic Imaging / methods
  • Diagnostic Imaging / standards
  • GPI-Linked Proteins
  • Mesothelioma / diagnosis
  • Methods
  • Mice
  • Models, Animal*
  • Osteopontin
  • Pleural Neoplasms / diagnosis

Substances

  • Biomarkers, Tumor
  • GPI-Linked Proteins
  • Osteopontin
  • mesothelin